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Abstract
Background: Patients with retinal diseases frequently complain of poor visual function even when visual acuity is
relatively unaffected. This clinical finding has been attributed to deficits in contrast sensitivity (CS). The purpose of
our study was to evaluate the CS in patients with clinical and genetic diagnosis of inherited retinal degeneration
(IRD) and relatively preserved visual acuity.
Methods: Seventeen patients (30 eyes) with IRD and visual acuity of 20/40 or better, and 18 controls (18 eyes)
without any ocular condition underwent slit lamp examination, visual acuity testing via standard Snellen chart
testing, CS testing via the Quick Contrast Sensitivity Function (QCSF), and Spectral Domain Optical Coherence
Tomography (SD-OCT). CS were measured at 1.0, 1.5, 3.0, 6.0, 12.0, and 18.0 cycles per degree (cpd). T tests with
general estimated equations were used to compare CS between groups. Wald chi square followed by pairwise
comparisons was used to compare CS between multiple groups.
Results: We included 12 patients with rod-cone dystrophy (RCD), 3 patients with Stargardt disease (STGD) and 2 patients
with Best disease. Patients with IRD had significantly worse CS than controls (p< 0.001) in all spatial frequencies. Patients
with STGD had more marked deficits in CS than patients with Best disease (p< 0.001) and RCD (p< 0.001) despite having
similar visual acuities.
Conclusion: Patients with IRD, especially patients with STGD with relatively preserved visual acuity have marked deficits in
CS when measured across a range of spatial frequencies. We recommend that clinical trials for STGD incorporate CS
measured over a range of spatial frequencies as a secondary clinical endpoint for monitoring visual function. CS may provide
an explanation for complaints of visual dysfunction when visual acuity is not significantly altered.
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Background
Patients with inherited retinal degeneration (IRD) often com-
plain of poor central vision, despite having a visual acuity near
20/20 [1–3]. One possible explanation could be deficiencies in
contrast sensitivity (CS) in these patients. However, there are a
number of ongoing clinical trials for patients with IRD where
the primary outcome measure is visual acuity improvement
or stability [4–6]. Studies on different ophthalmic conditions
have found deficits in CS when visual acuity is normal or near
normal [7–9], and CS testing provides an alternate method of
testing visual function [10–12]. Contrast sensitivity deficits
have been described for patients with retinitis pigmentosa [1,
13–19]. Others such as Yioti et al. described structural
changes observed on Spectral Domain Optical Coherence
Tomography (SD-OCT) corresponding to deficits of CS in pa-
tients with retinitis pigmentosa [15].
Contrast sensitivity is typically measured using the
Pelli-Robson charts, which only allow CS to be measured at
a limited number of spatial frequencies and therefore may
underestimate CS deficits. Although previous studies that
evaluated CS at different spatial frequencies in patients with
retinitis pigmentosa have found reductions at low and high
spatial frequencies, CS deficits were more likely to be found
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at the higher spatial frequencies [1, 13, 14, 19, 20]. Neverthe-
less, these studies have been limited to patients clinically
diagnosed with retinitis pigmentosa. Although previous
studies have looked at both chromatic and achromatic CS
in Stargardt disease (STGD) [21, 22], there is a paucity of
work to describe CS deficits across different spatial fre-
quencies in patients with macular dystrophies, such as
STGD and Best disease.
With the advent of new methods such as the Quick Con-
trast Sensitivity Function (QCSF) that provide a more com-
prehensive evaluation of CS losses at a greater number of
contrast and spatial frequency combinations [23], this study
aimed to compare CS deficits among patients with both a
clinical and a genetic diagnosis of an IRD and normal con-
trols who presented withVA acuities better than 20/40.
Methods
This study was conducted at the W. K. Kellogg Eye Center,
University of Michigan. The protocol design and conduct ad-
hered to the tenets of the Declaration of Helsinki. The study
was approved by the University of Michigan Medical
School’s Internal Review Board (HUM 12099). Patients were
recruited from the Kellogg Eye Center Inherited Retinal De-
generation Clinic between January and October of 2017.
Normal control patients were recruited as volunteers from
the University of Michigan’s Health Research Website. Writ-
ten informed consent was obtained from all subjects before
participation in the study.
Inclusion criteria for the study were that patients had a clin-
ical and a genetic diagnosis of an IRD and best-corrected vis-
ual acuity (BCVA) of 20/40 or better. Patients were excluded
if they presented with a refractive error exceeding ±6.00
diopter (D) spherical equivalent, more than 2 diopters of
keratometric astigmatism, had opacity of the ocular media
(nuclear, cortical, or posterior subcapsular lens opacity)
that is greater than grade 1 according to the Lens Opaci-
ties Classification System III system [24]; had a history of
any ocular or retinal diseases that could affect vision other
than the IRD (except for cystoid macular edema), or any
systemic or neurological disease that could affect vision,
had intraocular surgery in the past 3 months, and were
unable to provide informed consent. Inclusion and exclu-
sion criteria for control participants were the same except
that they had no known condition that could affect vision.
Patients younger than 18 years old were not included.
All patients underwent a comprehensive routine ocular
examination, which was performed by a retina specialist.
This included biomicroscopy of anterior and posterior seg-
ments, applanation tonometry, visual acuity (VA) using a
Snellen chart, and a dilated fundus examination with a 78
diopter non-contact lens (Volk ®). Spectral Domain Optical
Coherence Tomography (SD-OCT, Spectralis, Heidelberg
Engineering, Heidelberg, Germany) was performed to
evaluate the presence of cystoid macular edema (CME).
Demographic variables, including age, race, sex, and med-
ical conditions were also recorded.
Contrast sensitivity testing was assessed by the Quick
Contrast Sensitivity Function (QCSF) on the AST Sentio
platform (Adaptive Sensory Technology, United States).
The QCSF is a prototype of a quick contrast sensitivity
testing device that, unlike the standard Pelli-Robson chart,
allows the examiner to test CS over a wider variety of con-
trast levels and spatial frequency combinations [7].
During the test, the large-screen display was placed at a
distance of three meters and the patient’s distance vision was
corrected based on refraction. There were 25 trials, during
which the QCSF method presented triplets of filtered Sloan
letters at 128 contrast levels (0.002 to 100%) and 19 spatial
frequencies (approximately 1 to 27 cycles per degree, with
higher cycles per degree indicating smaller numbers) with an
overall possible 2432 stimuli [7]. The patients were asked to
read the letters, and the examiner recorded whether the an-
swer was correct or incorrect or if there was no answer pro-
vided. The QCSF device selected the optimal two-dimensional
contrast and spatial frequency combinations using a Bayesian
Adaptive Algorithm to update the probabilities of the CS
curve parameters. This enables the test to have a very high test
retest repeatability [23] . The test then calculates the Area
Under the Log Contrast Sensitivity Function (AULCSF) using
a built in algorithm [25], which integrates the contrast sensi-
tivity at 1.0 to 18 cpd. The AULCSF and the CS at 1.0, 1.5, 3.0,
6.0, 12.0, and 18.0 cpd were recorded for each eye and used
for statistical analysis.
Statistical analysis of data
Data were summarized with means and standard deviations
for continuous variables and counts and proportions for cat-
egorical variables. Comparisons involving only patient-level
(e.g., age, sex) were formally tested with Student’s t-test or
Fisher’s Exact Test. Comparisons involving eye-level data
(e.g., visual acuity, contrast sensitivity) utilized general esti-
mating equations (GEE) to allow for correlated measure-
ments. Multi-group comparisons (e.g., contrast sensitivity in
different diagnosis groups) were made by Wald chi-square
tests followed by pairwise comparisons, adjusted for multiple
comparisons. Statistical analyses were performed in R (R
Foundation for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
We included 17 patients (30 eyes) with IRD and 18 (18
eyes) controls. There were 12 patients with rod-cone dys-
trophy (RCD) caused by pathogenic variants in eight dif-
ferent genes (Table 1), three patients with STGD caused
by two pathogenic variants in the ABCA4 and two pa-
tients with Best disease caused by at least one pathogenic
variant in the BEST1. Four eyes of patients with IRD were
excluded because they did not meet visual acuity criteria.
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Characteristics of the patients with IRD and control group
are summarized in Table 1. Patients from the control
group were older than patients with IRD (p < 0.02) by a
mean of 10.7 years but had a similar sex ratio. The control
group had a better visual acuity than patients with IRD (p
< 0.0001). The average visual acuity for the IRD group cor-
responded to a 20/25 Snellen line, while for the control
group it was 20/16. There were no statistically significant
differences in visual acuity among the IRD subgroups.
Contrast sensitivity
Table 2 summarizes the performance on the QCSF for all pa-
tient groups. Patients with IRD had lower AULCSF than nor-
mal controls (p < 0.001). When comparing the CS at different
spatial frequencies, we found that patients with IRD had re-
duced CS at all spatial frequencies (p < 0.001) (Table 2). The
largest differences were found between 6.0 to 18.0 cpd.
When comparing the different IRD groups, we found that
patients with STGD had lower AULCSF than patients with
RCD (p < 0.001) and Best disease (p < 0.001) (Fig. 1) and sig-
nificant reductions at all spatial frequencies except 1.0 and
18.0 cpd (Table 2). The greatest differences were found at 3.0
and 6.0 cpd. There were no statistically significant differences
in CS between RCD and Best disease. Five patients RCD had
CME and 7 did not have it. Patients with CME had an average
AULCSF of 1.29, while those without CME had an average
AULCSF of 1.25. There were no statistically significant differ-
ences in CS in patients with RCD with CME and those with-
out CME (p> 0.3). The sample did not allow the analysis of
any statistically significant differences in CS among different
causative genes.
Discussion
In this study, we demonstrated that patients with IRD have
significant deficits in CS when visual acuity is relatively pre-
served. By using the QCSF test, we also showed that CS in
these patients is reduced in all spatial frequencies. We also
found the greatest reductions in CS at the higher spatial fre-
quencies (from 6.0 to 18.0), which is consistent with previous
studies [19]. These changes may be missed by Pelli-Robson
testing which at fewer spatial frequencies. Furthermore, pa-
tients with STGD had worse CS than patients with the other
IRDs, even though visual acuities were similar between IRD
subgroups. Our study therefore indicates that CS is not
merely a surrogate for visual acuity, as it can provide more
information about visual dysfunction in these patients than
visual acuity alone.
It is not clear why the patients with STGD had a worse CS.
Although the patients with STGD were on average older, they
were similar in age to control patients, in whom a similarly
poor CS was not seen, even though small deteriorations of CS
have been associated with aging [26]. This clinical finding for
STGD should be considered as future studies unveil the
pathogenesis of the disease and the mechanisms for visual
dysfunction, such as lipofuscin accumulation in the retinal pig-
ment epithelium, all trans retinal accumulation in the photore-
ceptors, loss of retinal pigment epithelium (RPE cells), and
loss of photoreceptor cells.
Table 1 This table summarizes the patient characteristics for the three dystrophy groups and healthy controls
Rod-cone dystrophy Stargardt disease Best disease Controls P value IRD vs control
N (%) 12 (22.2%) 3 (5.6%) 2 (3.7%) 18 (52.8%) NA
Age in years, mean (SD) 36.6 (15.9) 57.0 (13.7) 33.5 (14.4) 52.9 (11.6) P < 0.02a
Gender
Male, n (%) 5 (41.7%) 1 (33.3%) 1 (50.0%) 9, (47.3%) P = 0.74b
Female, n (%) 7 (58.3%) 2 (66.7%) 1 (50.0%) 10, (52.6%)
LogMAR visual acuity, Mean (SD) 0.10 (0.09) 0.18 (0.11) 0.15 (0.17) −0.10 (0.07) P < 0.0001c










cWald test based on GEE model
NA not applicable
IRD Inherited retinal degeneration
This table summarizes the patient characteristics for the three dystrophy groups and healthy controls
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Although a variety of studies have measured CS when vis-
ual acuity is near 20/20 [7, 27, 28], it is unclear to date what
aspect of retinal neuronal function is assessed by CS. It may
be that visual acuity only requires a small number of func-
tioning cones in the fovea, while intact CS requires a greater
number of intact cones throughout the macula. This may ex-
plain why the patients with STGD had a worse CS, as foveal
cones may be affected earlier in the disease course [29].
There may also be image processing by inner retinal layers
that contribute to CS.
It is also unclear why patients with RCD and CME did not
have more alterations in the CS than those without CME.
There have been a variety of studies in which CS was reduced
in the presence of CME from diseases like diabetic retinopathy
or acute central serous retinopathy [28, 30]. It may be that the
CS depends on the severity of the edema on OCT. It could
Table 2 This table summarizes the contrast sensitivity for the patient groups
Controls Rod-cone dystrophy Best Disease Stargardt Disease (STGD) P-value dystrophy versus controls P value STGD vs other IRD
AULCSF 1.58 (0.15) 1.27 (0.20) 1.23 (0.32) 0.61 (0.27) P < 0.0001 P < 0.001
1.0cpd 1.67 (0.10) 1.50 (0.12) 1.46 (0.20) 1.19 (0.25) P < 0.0001 0.179
1.5 cpd 1.73 (0.10) 1.56 (0.13) 1.50 (0.25) 1.10 (0.22) P < 0.0001 P < 0.001
3.0 cpd 1.77 (0.10) 1.54 (0.16) 1.46 (0.29) 0.84 (0.22) P < 0.0001 P < 0.0001
6.0 cpd 1.60 (0.17) 1.27 (0.24) 1.23 (0.34) 0.45 (0.36) P < 0.0001 P < 0.0001
12.0 cpd 1.08 (0.25) 0.63 (0.31) 0.65 (0.37) 0.19 (0.38) P < 0.0001 P = 0.04
18.0 cpd 0.60 (0.31) 0.16 (0.23) 0.22 (0.25) 0.08 (0.17) P < 0.0001 P = 1.00
The means (standard deviations) for the AULCSF and contrast sensitivity at each spatial frequency in cycles per degree (cpd) are provided. P-values are from Wald
test based on GEE model
AULCSF Area Under the Log Contrast Sensitivity Function
IRD Inherited retinal degeneration
STGD Stargardt disease
Cpd cycles per degree
GEE general estimating equations
This table summarizes the contrast sensitivity for the patient groups. The means (standard deviations) for the AULCSF and contrast sensitivity at each spatial
frequency (in cpd) are provided. P-values are from Wald test based on GEE model
Fig. 1 This figure depicts QCSF graphs for age matched subjects with contrast sensitivity on the y axis and spatial frequencies (in cpd) on the x axis. The graph
on the left is from a patient with STGD; in the center from a patient with RCD; and on the right is from a control subject. The line is the best fitting contrast
sensitivity function with the confidence interval shaded in grey. The green triangles represent the stimuli that the subject captured correctly, the red crosses
represent the stimuli that the patient read incorrectly, and the black crosses represent the stimuli that the subject could not read altogether. The patients with
STGD had the worst CS function (curve with lower values and smallest area) of all groups. We did not include a CS graph from a patient with Best disease
since these patients had an almost identical CS function to patients with RCD
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also be that CS is dependent on the state of the photorecep-
tors, and thus the pathology causing both the photoreceptor
dysfunction and the edema may be important. Further struc-
tural studies using SD-OCT in more patients are needed, so
that the severity and duration of CME can also be associated
with reductions in CS in IRDs.
Current endpoints for therapeutic trials for STGD use visual
acuity (ETDRS) and CS using Pelli-Robson charts to measure
central visual function. Since Pelli-Robson charts measure CS
at a limited number of spatial frequencies, the magnitude of
the visual burden and variations of CS may go undetected in a
clinical trial setting that uses only Pelli-Robson as a method to
measure CS. Other laboratory methods for assessing CS that
use multiple spatial frequencies, such as the VCTS chart, are
time-consuming and less practical for use in clinics [23]. The
QCSF overcomes some of these inefficiencies and can be used
in therapeutic trials as a secondary outcome measure and in
clinical practice to demonstrate and monitor unrecognized
visual burden from IRD, especially in patients with STGD.
A limitation of our study was the small sample size due to
the difficulty of finding patients that met inclusion criteria for
the study. It is possible that the specific gene mutations along
with the disease severity could affect CS in patients with IRDs,
but the sample size is too small to study the effects of different
mutations on CS. The small sample size also meant that we
could not run a detailed structural analysis of which deficits
on SD-OCT were associated with a worse CS in patients with
STGD. Due to the sample size, we also cannot make conclu-
sions about CS deficits between patients with STGD and the
other mutation proven IRDs. Another limitation for this study
is that we did not examine test-re test variability. However,
previous studies have reported a very high test retest repeat-
ability with the QCSF [7, 23]. The patients from control
group had a better acuity than the patients with IRD.
Thus, it is unclear whether the CS would have been worse
if the average acuities were the same. However, patients
with STGD had similar acuities to the other IRD groups
and yet had a worse CS.
Conclusions
In conclusion, patients with IRD, especially patients with
STGD with relatively preserved visual acuity were found to
have marked abnormalities in CS when tested across differ-
ent spatial frequencies. We recommend that clinical trials
for STGD incorporate CS tested across different spatial fre-
quencies as a secondary clinical endpoint. Future studies
should also correlate the pathogenesis of this disease to the
severe losses in CS.
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